Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations

HIV Clinical Trials

Volumn 7, Issue 1, 2006, Pages 34-38

  Smith, Don E ^a   Jeganathan, Sarangapany ^a   Ray, John ^b  

^a Albion Street Centre ^*  (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Atazanavir; Bilirubin; HIV; Therapeutic drug level monitoring; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BILIRUBIN; RITONAVIR; TENOFOVIR;

ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SAMPLE SIZE;

BILIRUBIN; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; STATISTICS, NONPARAMETRIC;

EID: 33646596272     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/0KX0-H9VH-99EE-5D0L     Document Type: Article

References (17)

1. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17(18):2603-2614.
2. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011-1019.
3. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685-694.
4. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292(2):251-265.
5. Gibbons S, Robinson L, Dickinson L, et al. Therapeutic drug monitoring of atazanavir in routine clinical setting in UK. In: Program and abstracts of the International Congress on Drug Therapy in HIV; 2004; Glasgow, Scotland.
6. Gonzalez D, Bonora S, Canta F, et al. Atazanavir C trough is associated with efficacy and safety: definition of therapeutic range. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston.
7. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005;56(2):380-387.
8. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36(2):684-692.
9. Jeganathan S, Smith D, Gold J. Early clinical experience with atazanavir in treatment experienced patients. Sexual Health. 2006;3:33-35.
10. Cateau E, Tournier N, Dupuis A, Le Moal G, Venisse N. Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography. J Pharm Biomed Anal. 2005;39(3-4):791-795.
11. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1975.
12. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pre-treated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48(6):2091-2096.
13. Bristol-Meyers Squibb Company. Reyataz (Atazanavir Sulfate) Product Information Guide; 2003.
14. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;1 5(1):71-75.
15. Boyd MA, Siangphoe U, Ruxrungtham K, et al. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med. 2005;6(6):410-420.
16. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15(18):2441-2444.
17. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5(4):201-205.